Daniel Allen Gold
Director · Roivant Sciences Ltd.
- 2025
- Sep 18, 2026
- 8
Summary
Latest filing:
Daniel Allen Gold is Director of Roivant Sciences Ltd. (ROIV). 8 SEC Form 4 filings on record going back to 2025, most recently on 18 September 2026. Most recent open-market trade: sold $4.10M of ECO on 17 August 2026. Lifetime open-market sales: $152.04M.
Recent transactions
20The latest 20 SEC Form 4 transactions reported by Daniel Allen Gold.
Trading pattern
InsiderAlpha's records for Daniel Allen Gold go back to 2025: 8 primary Form 4 filings, an average of 4.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Daniel Allen Gold files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Keith S. Manchester - $154.47M in ROIV purchases and sales in the last 12 months
- QVT Financial LP - $147.38M in ROIV purchases and sales in the last 12 months
- Mayukh Sukhatme - $109.13M in ROIV purchases and sales in the last 12 months
- Frank Torti - $82.04M in ROIV purchases and sales in the last 12 months
- Eric Venker - $65.62M in ROIV purchases and sales in the last 12 months
- Matthew Gline - $46.17M in ROIV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Daniel Allen Gold?
Daniel Allen Gold is a corporate insider, tracked as Director of Roivant Sciences Ltd. (ROIV). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Daniel Allen Gold submitted recently?
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Daniel Allen Gold been buying or selling stock?
Recorded transactions: 0 open-market purchases and 21 open-market sales ($152.04M) across all tracked filings.